Medical Imaging (MEDD) 10-Q 14 Nov 17 2017 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2017	Nov. 10, 2017
Document And Entity Information
Entity Registrant Name	MEDICAL IMAGING CORP.
Entity Central Index Key	1,370,804
Document Type	10-Q
Document Period End Date	Sep. 30, 2017
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		32,496,481
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2,017

Consolidated Balance Sheets (Un

Consolidated Balance Sheets (Unaudited) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Current Assets
Cash and Cash Equivalents	$ 27,980	$ 85,455
Accounts Receivable, net of allowance for doubtful accounts	1,097,539	1,106,712
Prepaid Expenses	15,276	43,087
Total Current Assets	1,140,795	1,235,254
Property and Equipment, net of accumulated depreciation	1,801,266	2,100,058
Goodwill	1,977,670	1,977,670
Deposits	25,152	18,563
TOTAL ASSETS	4,944,883	5,331,545
Current Liabilities
Accounts Payable	2,071,556	1,772,752
Accrued Liabilities	866,794	706,572
Current Portion of Capital Lease Obligations	148,675	123,738
Current Portion of Promissory Notes	331,405	931,842
Current Portion of Promissory Notes, Overdue	539,000	0
Current Portion of Royalty Financing	1,181,811	752,926
Current Portion of Convertible Notes	145,075	2,223,706
Current Portion of Convertible Notes, Overdue	2,094,000	0
Total Current Liabilities	7,378,316	6,511,536
Long Term Liabilities
Capital Lease Obligations, less current portion	137,004	200,536
Promissory Notes, less current portion, net of unamortized discounts	364,291	112,000
Royalty Financing, less current portion, net of unamortized discounts	1,144,637	1,254,498
Convertible Notes, less current portion, net of unamortized discounts	208,517	142,357
Total Liabilities	9,232,765	8,220,927
Commitments and Contingencies
Stockholders' Deficit
Preferred Stock	0	0
Common Stock	32,497	25,742
Additional Paid-In Capital	2,226,058	2,057,723
Accumulated Other Comprehensive Income	180,462	138,145
Accumulated Deficit	(6,726,899)	(5,110,992)
Total Stockholders' Deficit	(4,287,882)	(2,889,382)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 4,944,883	$ 5,331,545

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Statement of Financial Position [Abstract]
Preferred stock, par value in dollars	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value in dollars	$ 0.001	$ 0.001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	32,496,481	25,741,481
Common stock, shares outstanding	32,496,481	25,741,481
Doubtful accounts, accounts receivable	$ 574,545	$ 475,982
Accumulated depreciation, property and equipment	1,900,916	1,562,471
Unamortized discount, promissory notes	201,624	120,000
Royalty financing, unamortized discount	4,983,828	5,302,853
Unamortized debt discount, convertible notes	$ 327	$ 2,634

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Revenue:
Sales	$ 1,800,858	$ 1,819,039	$ 5,396,157	$ 5,651,562
Cost of Sales	1,111,597	978,546	3,125,913	2,864,662
Gross Margin	689,261	840,493	2,270,244	2,786,900
Operating Expenses:
Labor	343,261	303,149	971,724	951,321
General and Administrative	197,204	176,564	529,560	586,806
Rent Office Space and Servers	146,848	134,715	430,792	413,650
Depreciation	144,604	140,550	440,469	418,298
Legal and Professional	56,181	54,797	161,248	227,267
Advertising	38,652	37,791	89,083	65,683
Insurance	23,195	22,284	69,877	67,729
Bad Debt Expense	13,764	1,219	98,831	1,219
Travel	8,139	14,461	38,599	33,857
Management Fees	5,389	5,100	13,851	15,300
Total Operating Expenses	977,237	890,630	2,844,034	2,781,130
Income (Loss) from Operations	(287,976)	(50,137)	(573,790)	5,770
Other Income and (Expenses):
Other Income	(539)	3,992	31,149	60,083
Foreign Currency Gains (Losses)	(11,438)	(595)	(74,140)	(39,846)
Write-off Fixed Assets	(99,432)	0	(99,432)	0
Interest & Penalties Expense	(127,726)	(123,832)	(411,989)	(357,832)
Amortization of Debt Discount	(174,695)	(117,348)	(487,705)	(375,140)
Total Other Income (Expenses)	(413,830)	(237,783)	(1,042,117)	(712,735)
Net Loss	(701,806)	(287,920)	(1,615,907)	(706,965)
Comprehensive Income	(12,495)	28,738	42,317	96,917
Total Comprehensive Loss	$ (714,301)	$ (259,182)	$ (1,573,590)	$ (610,048)
Basic and Diluted Loss per Share	$ (0.023)	$ (0.010)	$ (0.058)	$ (0.024)
Weighted Average Shares Outstanding - Basic and Diluted	30,532,892	25,641,481	27,048,006	25,555,237

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
CASH FLOWS FROM OPERATING ACTIVITIES:
Net Income (Loss)	$ (1,615,907)	$ (706,965)
Adjustments to Reconcile Net Loss to Net Cash from Operating Activities:
Depreciation	440,469	418,298
Write-off Fixed Assets	99,432	0
Bad Debt Expense	98,831	0
Amortization of Debt Discount	487,705	375,140
Stock-based compensation	62,850	5,000
Foreign currency transaction (Gain) Loss	(5,087)	(4,418)
Changes in operating assets and liabilities:
Accounts Receivable, Net of Allowance for Doubtful Accounts	(89,658)	(583,887)
Prepaid Expenses	27,811	(2,456)
Accounts Payable and Accrued Liabilities	459,026	444,848
NET CASH AND CASH EQUIVALENTS FROM OPERATING ACTIVITIES	(34,528)	(54,440)
CASH FLOWS FROM INVESTING ACTIVITIES:
Deposit on Equipment	0	(5,000)
Equipment Purchase	(184,339)	(102,847)
NET CASH FROM INVESTING ACTIVITIES	(184,339)	(107,847)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from Promissory Notes	457,225	1,020,000
Proceeds from Convertible Debt	153,000	0
Royalty Fee Payment	0	(182,933)
Principal Payments on Promissory Notes	(361,587)	(639,650)
Principal Payments on Convertible Notes	(35,000)	(5,000)
Principal Payments on Capital Lease Obligations	(94,563)	(185,470)
NET CASH AND CASH EQUIVALENTS FROM FINANCING ACTIVITIES	119,075	6,947
Gain (Loss) due to foreign currency translation	42,317	96,917
NET CHANGE IN CASH AND CASH EQUIVALENTS	(57,475)	(58,423)
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	85,455	109,914
CASH AND CASH EQUIVALENTS AT END OF PERIOD	27,980	51,491
Cash paid during the year for:
Interest	91,052	227,538
Income Taxes	0	51,187
Non-cash financing and investing activities:
Shares Issued for Convertible Note	112,240	9,030
Warrants Issued for Converted Notes	0	285
Equipment purchased under Capital Lease	55,968	16,618
Accrued Interest Converted into Note	$ 0	$ 15,000

Organization and Summary of Sig

Organization and Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Summary of Significant Accounting Policies	Note 1. Organization and Summary of Significant Accounting Policies Organization and Basis of Presentation Medical Imaging Corp., (“MIC” or the “Company”), a Nevada Corporation was incorporated in 2000. In 2005, the Company developed a business plan for private healthcare opportunities in Canada with the objective of owning and operating private diagnostic imaging clinics. In 2009, the Company purchased Canadian Teleradiology Services Inc., which operates as: Custom Teleradiology Services (“CTS”). CTS provides remote reading of medical diagnostic imaging scans for rural hospitals and clinics in Canada. In early 2010, the Company modified its business plan to grow its CTS subsidiary while commencing the acquisition of existing full service imaging clinics located in the United States and exploring the development of new diagnostic imaging technology. In 2012, the Company purchased Schuylkill Open MRI Inc., which operates as: Schuylkill Medical Imaging (“SMI”), an independent diagnostic imaging facility located in Pottsville, Pennsylvania. In 2014, the Company purchased Partners Imaging Center of Venice, LLC (“PIV”) located in Venice, Florida; Partners Imaging Center of Naples, LLC (“PIN”) located in Naples, Florida; and Partners Imaging Center of Charlotte, LLC (“PIC”) located in Port Charlotte, Florida. Basis of Presentation These consolidated financial statements and related notes are presented in accordance with accounting principles generally accepted in the United States, and are expressed in U.S. dollars. The Company’s fiscal year-end is December 31. Principle of Consolidation The consolidated financial statements include the accounts of Medical Imaging, Corp., and its wholly-owned subsidiaries, CTS, SMI, PIV, PIN, and PIC. Intercompany accounts and transactions have been eliminated in the consolidated financial statements. CTS’, SMI’s, PIV’s, PIN’s, and PIC’s accumulated earnings prior to their acquisitions are not included in the consolidated balance sheet. Use of Estimates and Assumptions The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) requires management to make estimates and assumptions that affect (i) the reported amounts of assets and liabilities, (ii) the disclosure of contingent assets and liabilities known to exist as of the date the consolidated financial statements are published, and (iii) the reported amount of net sales, expenses and costs recognized during the periods presented. Adjustments made with respect to the use of estimates often relate to improved information not previously available. Uncertainties with respect to such estimates and assumptions are inherent in the preparation of consolidated financial statements; accordingly, actual results could differ from these estimates. Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. At September 30, 2017, and December 31, 2016, cash includes cash on hand and cash in the bank. Accounts Receivable Credit Risk The allowance for doubtful accounts is maintained at a level sufficient to provide for estimated credit losses based on evaluating known and inherent risks in the receivables portfolio. Management evaluates various factors including expected losses and economic conditions to predict the estimated realization on outstanding receivables. In connection with the acquisition of the three facilities located in Venice, Port Charlotte and Naples, Florida, the Company, in October 2014, entered into professional services agreements whereby the seller of those three facilities continued to handle the billing and collection for the imaging centers (the “third party billing”). The seller must still provide a full set of verification data to the Company with respect to its account receivable processing and collections so that the Company can determine the extent to which accounts submitted by the seller in connection with the third party billing have been collected or denied. Final verification will only be able to be completed after the conclusion of the services performed pursuant to the third party billing contract, and review of account balances which is expected during the 2017 fiscal year. As of September 30, 2017 and December 31, 2016, the allowance for doubtful accounts from direct billings was $299,545 and $200,982, respectively. The allowance for doubtful accounts from third party billings (Florida operations) was $275,000 in both periods. Although the gross receivable balance has increased significantly, management is actively pursuing collection efforts directly with patients and insurance payers and believes that the current allowance for doubtful accounts is sufficient to cover any expected losses. Goodwill and Indefinite - Lived Intangible Assets The Company follows the provisions of Financial Accounting Standard Accounting Standards Codification (“ASC”) 350, Goodwill and Other Intangible Assets No goodwill impairment was recognized during 2017 or 2016. Revenue Recognition The Company holds contracts with several hospitals and groups of health care facilities to provide Teleradiology services for a specific period of time. The Company bills for services rendered on a monthly basis. For the three and nine months ended September 30, 2017, CTS held six contracts; four contracts that are renewable on a year-to-year basis and one contract that automatically renewed in 2016 for a successive one year term, and one to be renewed in 2018. In accordance with the requirement of Staff Accounting Bulletin (“SAB”) 104, the Company recognizes revenue when: (1) persuasive evidence of an arrangement exists (contracts); (2) delivery has occurred (monthly); (3) the seller’s price is fixed or determinable (per the customer’s contract, and services performed); and (4) collectability is reasonably assured (based upon our credit policy). Revenue is accounted for under the guidelines established by SAB 101, Revenue Recognition in Financial Statements, Revenue Recognition Cost of Sales Cost of sales includes fees paid to radiologists for reading services, transcription fees, equipment repairs, system license and usage costs. Impairment of Long-Lived Assets In accordance with ASC 360, Property, Plant and Equipment, Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset. Convertible Debentures Debt – Debt with Conversion and Other Options The Company accounts for modifications of its Embedded Conversion Features in accordance with ASC 470-50, Debt – Modifications and Exchanges, , Debt – Modification and Exchanges – Extinguishment of Debt Stock Based Compensation The Company follows ASC 718, Stock Compensation The Company measures all share-based payments to employees (which includes non-employee Board of Directors), including employee stock options, warrants and restricted stock, at the fair value of the award and expenses it over the requisite service period (generally the vesting period). The fair value of common stock options or warrants granted to employees is estimated at the date of grant using the binomial option pricing model (“BOPM”). The calculation also takes into account the common stock fair market value at the grant date, the exercise price, the expected life of the common stock option or warrant, the dividend yield and the risk-free interest rate. The Company from time to time may issue stock options, warrants and restricted stock to acquire goods or services from third parties. Restricted stock, options or warrants issued to other than employees or directors are recorded on the basis of their fair value. The options or warrants are valued using the BOPM on the basis of the market price of the underlying equity instrument on the “valuation date,” which for options and warrants related to contracts that have substantial disincentives to non-performance, is the date of the contract, and for all other contracts is the vesting date. Expenses related to the options and warrants are recognized on a straight-line basis over the period which services are to be received. There was no stock-based compensation expense to non-employees for the three months ended September 30, 2017, and 2016. For the three months ended September 30, 2017 and 2016, the Company recognized stock based compensation expenses from stock granted to employees of $23,750 and $0, respectively. There was no stock-based compensation expense to non-employees for the nine months ended September 30, 2017, and 2016. For the nine months ended September 30, 2017, the Company recognized stock-based compensation expenses of $8,500 from stock options and $30,600 from stock granted to employees. The options were valued using the BOPM and included in the labor operating expenses in the consolidated statements of operations. For the nine months ended September 30, 2016, the Company recognized stock based compensation expenses from stock granted to employees of $5,000. Fair Value of Financial Instruments The fair value of a financial instrument is the amount at which the instrument could be exchanged in a current transaction between willing parties other than in a forced sale or liquidation. The carrying amounts of the Company’s financial instruments, including cash, accounts receivable, prepaid expenses, accounts payable, accrued liabilities and notes and loans payable approximate fair value due to their most maturities. Fair Value Measurements The Company follows ASC 820, Fair Value Measurements and Disclosures Level 1 Quoted market prices available in active markets for identical assets or liabilities as of the reporting date. Level 2 pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date. Level 3 pricing inputs that are generally observable inputs and not corroborated by market data. The carrying amounts of the Company’s financial assets and liabilities, such as cash and accounts payable approximate their fair values because of the short maturity of these instruments. The Company does not have assets and liabilities that are carried at fair value on a recurring basis. Foreign Currency Translation The Company’s functional currency for its wholly-owned subsidiary, CTS, is the Canadian dollar, and their financial statements have been translated into U.S. dollars. The Canadian dollar based accounts of the Company’s foreign operations have been translated into United States dollars using the current rate method. Assets and liabilities of those operations are translated into U.S. dollars using exchange rates as of the balance sheet date; income and expenses are translated using the weighted average exchange rates for the reporting period. Translation adjustments are recorded as accumulated other comprehensive income (loss), a separate component of stockholders’ equity. The Company recognized a foreign currency gain (loss) on transactions from operations of $(11,438) for the three months ended September 30, 2017 and $(595) for the three months ended September 30, 2016. The Company recognized other comprehensive income (loss) of $(12,495) for the three months ended September 30, 2017 and $28,738 for the three months ended September 30, 2016. The Company recognized a foreign currency gain (loss) on transactions from operations of $(74,140) for the nine months ended September 30, 2017 and $(39,846) for the nine months ended September 30, 2016. The Company recognized other comprehensive income (loss) of $42,317 for the nine months ended September 30, 2017 and $96,917 for the nine months ended September 30, 2016. Income Taxes The Company accounts for income taxes in accordance with ASC 740, Income Taxes Net Income (Loss) Per Share The Company follows the provisions of ASC 260, Earnings per Share Basic earnings per share is computed by dividing net income available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share reflects the potential dilution that could occur if stock options and other commitments to issue common stock were exercised or equity awards vest resulting in the issuance of common stock or conversion of notes into shares of the Company’s common stock that could increase the number of shares outstanding and lower the earnings per share of the Company’s common stock. This calculation is not done for periods in a loss position as this would be antidilutive. Recent Accounting Updates The Company does not expect the adoption of any recently issued accounting pronouncements to have a significant impact on its results of operations, financial position or cash flow.

Interim Financial Statements

Interim Financial Statements	9 Months Ended
	Sep. 30, 2017
Quarterly Financial Information Disclosure [Abstract]
Interim Financial Statements	Note 2. Interim Financial Statements The accompanying interim unaudited condensed financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In our opinion, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three and nine month period ended September 30, 2017 are not necessarily indicative of the results that may be expected for the year ending December 31, 2017. For further information, refer to the financial statements and footnotes thereto included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2016.

Property and Equipment

Property and Equipment	9 Months Ended
	Sep. 30, 2017
Property, Plant and Equipment [Abstract]
Property and Equipment	Note 3. Property and Equipment Property and equipment are stated at cost. Depreciation is calculated using the straight - line method over the estimated useful life of the assets. At September 30, 2017 and December 31, 2016, the major class of property and equipment were as follows: September 30, 2017 December 31, 2016 Estimated useful lives Computer/Office Equipment $ 529,851 $ 474,887 3-7 years Medical Equipment 2,301,351 2,329,872 3-7 years Leasehold Improvements 870,980 857,770 5-39 years Less: Accumulated Depreciation (1,900,916) (1,562,471) Net Book Value $ 1,801,266 $ 2,100,058 Depreciation expense was $144,604 and $140,550 for the three months ended September 30, 2017 and 2016, respectively. Depreciation expense was $440,469 and $418,298 for the nine months ended September 30, 2017 and 2016, respectively. For the nine months ending September 30, 2017 the Company has made purchases of $201,463 in equipment, $12,639 in leasehold improvements, and $26,205 in computer/office equipment. For the nine months ending September 30, 2017 the Company has written off a total of $206,420 in equipment.

Operating Lease Commitments

Operating Lease Commitments	9 Months Ended
	Sep. 30, 2017
Leases, Operating [Abstract]
Operating Lease Commitments	Note 4. Operating Lease Commitments Leases, CTS has a lease commitment for its new office space in Toronto, Canada of approximately $2,600 minimum rental per month, not including utilities, realty taxes, and operating costs. The lease will expire April 30, 2021. SMI entered into a lease commitment for its office space in Pottsville, Pennsylvania. The lease will expire on July 30, 2021. Monthly rental amounts are $6,908 per month not including utilities, realty taxes, and operating costs. SMI has a lease for its x-ray equipment space in Pottsville, Pennsylvania. The lease term is seven years from commitment date of October 2014. Monthly lease payments are $3,000. SMI has a lease for use of x-ray equipment and space in Pottsville, Pennsylvania. The lease term is two years from commitment date of January 2016. Monthly lease payments are $2,000. PIV has a lease for office space in Venice, Florida. The lease will expire September 30, 2021. Monthly rental amounts are $13,170 per month. PIN has a lease for office space in Naples, Florida. The lease will expire January 1, 2020. Monthly rental amounts are $9,543 per month. PIC has a lease for office space in Port Charlotte, Florida. The lease will expire June 20, 2021. Monthly rental amounts are $5,512 per month. Expected lease commitments as of September 30, 2017: Year Total 2017 $ 101,979 2018 435,062 2019 430,599 2020 355,177 2021 217,263 Thereafter - $ 1,540,080

Capital Lease Obligations

Capital Lease Obligations	9 Months Ended
	Sep. 30, 2017
Leases, Capital [Abstract]
Capital Lease Obligations	Note 5. Capital Lease Obligations A detailed summary of the capital lease obligations is as follows: Description Monthly payments Maturity Date APR * September 30, 2017 Balance December 31, 2016 Balance SMI X-Ray Machine $ 1,495 15-Aug-19 6.32 % $ 32,312 $ 43,930 SMI PACS/RIS System 3,115 1-Nov-19 5.69 76,028 100,240 SMI Copier 135 1-Aug-18 27.63 1,299 2,144 SMI Ascentrium 2,450 18-Nov-18 21.48 28,830 44,776 PIV,PIN,PIC PACS/RIS 3,094 1-Jan-20 4.22 82,368 107,170 PIV,PIN,PIC Computers 813 1-Nov-17 10.52 1,612 8,509 PIV,PIN,PIC Digital Printers 423 24-Feb-19 9.90 6,680 9,856 CTS Computers 554 2-Feb-18 2.25 2,915 7,649 PIN CT Lease 2,332 1-Aug-19 0 % 53,635 Total $ 14,411 $ 285,679 $ 324,274 *Annual Percentage Rate (“APR”). Minimum future lease payments under the capital leases as of September 30, 2017, are as follow: Minimum Lease Payments Total 2017 $ 42,517 2018 153,079 2019 102,857 2020 3,094 Total minimum lease payments 301,547 Less amount representing interest 15,868 Present value of minimum lease payments 285,679 Less current portion of minimum lease payments 148,675 Long-term capital lease obligations at September 30, 2017 $ 137,004

Promissory Notes

Promissory Notes	9 Months Ended
	Sep. 30, 2017
Debt Disclosure [Abstract]
Promissory Notes	Note 6. Promissory Notes A detailed summary of the promissory notes is as follows: Issuance Date Maturity Date APR 1 Payment Amount Payments Frequency September 30, 2017 Face Value Balance December 31, 2016 Face Value Balance 16-Feb-16 23-Feb-17 2 12.00 % $ 1,000 Monthly $ 100,000 $ 100,000 22-Feb-16 31-Aug-17 2 25.00 10,417 Monthly 500,000 500,000 22-Mar-16 22-Mar-17 2 12.00 700 Monthly 70,000 70,000 1-Jul-16 1-Aug-17 2 20.00 20,000 Monthly 280,000 400,000 3-Oct-16 27-Dec-17 42.09 2,255 Weekly - 117,261 18-May-17 1-Jul-19 3 20.00 $ 15,000 Monthly* 165,000 - 28-Jul-17 26-Jul-18 39.00 1,419 Daily 233,151 - 7-Aug-17 16-Oct-18 33.00 213 Daily 55,754 - 8-Sep-17 30-Mar-18 19.00 % 3,667 Weekly 92,415 - Total Face Value 1,436,320 1,187,261 Unamortized Discount (201,624) (143,419) Total $ 1,234,696 $ 1,043,842 1 2 3 Following are maturities of the long –term debt as of September 30, 2017: Principal Payments 2017 $ 860,244 2018 471,076 2019 105,000 Total $ 1,436,320

Convertible Notes

Convertible Notes	9 Months Ended
	Sep. 30, 2017
Debt Disclosure [Abstract]
Convertible Notes	Note 7. Convertible Notes On December 1, 2015, the holders of $1,840,000 Series B Notes have agreed to extend the maturity date of the debt outstanding to July 1, 2017 from its original maturity date of December 31, 2015. As part of the extension the Company issued warrants to entitle the holders to purchase up to 1,840,000 shares of common stock at an exercise price of $0.07 per share at any time from December 1, 2015 to July 1, 2018. The Company has valued the warrants at $0.0058 per issued share, and recorded a total discount of $10,672 that was amortized over the 18-month extension period. The notes principal balance was due July 1, 2017 and it is currently overdue. On May 12, 2017 $60,237 of the notes that were issued on December 5, 2012 was sold to a third-party investor. As part of the sale, the Company has agreed to reduce the conversion price from $0.10 per share to $0.025 per share. Convertible debt is accounted for under ASC 470, Debt – Debt with Conversion and Other Options On March 31, 2016, the holders of $50,000 Series B Notes have agreed to extend the maturity date of the debt outstanding to September 1, 2017 from its original maturity date of March 31, 2016. As part of the extension, the Company issued warrants to entitle the holders to purchase up to 50,000 shares of common stock at an exercise price of $0.07 per share at any time from March 31, 2016 to September 30, 2018. The Company has valued the warrants at $0.00278 per issued share, and recorded a total discount of $139 to be amortized over the 18-month extension period. . The notes principal balance was due September 1, 2017 and it is currently overdue. On March 31, 2016, the holder of $25,000 Series B Notes has agreed to extend the maturity date of the debt outstanding to September 1, 2019 from its original maturity date of March 31, 2016. As part of the extension the Company issued warrants to entitle the holders to purchase up to 25,000 shares of common stock at an exercise price of $0.07 per share at any time from March 31, 2016 to September 30, 2019. The Company has valued the warrants at $0.00583 per issued share, and recorded a total discount of $146 to be amortized over the 30-month extension period. On May 22, 2014, the Company sold, through private placement to accredited investors, three year 12% convertible notes (“Series C Notes”) in the aggregate principal amount of $95,000. The Notes bear interest at a rate of 12% per annum, payable to the holder at1% per month, with the principal amount due on May 31, 2017. The Notes are convertible into shares of the Company’s common stock at an initial conversion rate of $0.15 per share. In addition, each holder of Series C Notes received shares dependent on the dollar amount of Notes purchased. On August 25, 2014, October 31, 2014 and February 17, 2015, the Company sold an additional $75,000, $50,000 and $20,000, respectively of Series C Notes. The total number of shares of common stock issued was 240,000 shares. The notes principal balance was due May 31, 2017 and it is currently overdue. On March 26, 2014, the Company issued a $300,000 convertible note to a non-affiliate. The note pays interest at a rate of 12% per annum, payable to the holder at 1% per month. In addition to interest payments, the Company is making monthly payments of $5,000 towards the principal balance beginning June 1, 2014 until the note due date of February 28, 2018. The note is convertible into common shares of the Company at $0.15 per share. In addition, the purchaser of the note received 300,000 shares as part of the note agreement. As of September 30, 2017, principal balance of the note was $125,000. In accordance with ASC 470, Debt with conversion and other options, In accordance with ASC 480, Distinguishing Liabilities from Equity, • The debt can be transferred without the transfer of the warrants. • • In accordance with ASC 470, if the warrants issued on extension of series B notes are classified as equity, then the proceeds should be allocated based on the relative fair values of the base instrument. The warrants were valued at $0.00583 per issued share, and recorded a total discount of $10,672 to be amortized over to 18 month extension period. Amortization of the discount for the nine months ended September 30, 2017 and 2016 was $3,545 and $0, respectively. On July 7, 2017 the Company issued a $153,000 convertible note to a non-affiliate. The note pays interest at a rate of 12% per annum, payable at maturity. The note holder has the right at any time following the initial 180 days of note issuance, to convert all or any part of the outstanding and unpaid principal amount of this note to shares of common stock. The conversion price shall equal the variable conversion price of 65% multiplied by the market price. The market price shall mean the average of the lowest three (3) VWAP’s for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. “VWAP” shall mean the daily dollar volume-weighted average sale price for the common stock on the principal market on any particular trading day. Conversion is subject to limitation of 4.99% beneficial ownership of the outstanding shares of common stock. The note maturity is January 5, 2019. Prepayment on the note within one hundred twenty-one (121) day from the issue date and ending one hundred eighty (180) days following the issue day is subject to 120% Prepayment amount, as such $30,600 has been recorded and added to the note carrying value as of September 30, 2017, the note is presented with the total amount of $183,600. A detailed summary of the convertible notes is as follows: Issuance Date Maturity Date APR Conversion Rate Monthly Payment September 30, 2017 Face Value Balance December 31, 2016 Face Value Balance 3-Dec-12 1-Jul-17 12.00 % $ 0.10 $ 250 $ 25,000 $ 25,000 27-Mar-13 1-Jul-17 12.00 0.10 750 75,000 75,000 3-Dec-12 1-Jul-17 12.00 0.10 250 50,000 50,000 3-Dec-12 1-Jul-17 12.00 0.10 340 34,000 50,000 3-Dec-12 1-Jul-17 12.00 0.10 250 25,000 25,000 3-Dec-12 1-Jul-17 12.00 0.10 250 25,000 25,000 3-Dec-12 1-Jul-17 12.00 0.10 250 25,000 25,000 3-Dec-12 1-Jul-17 12.00 0.10 15,000 1,500,000 1,500,000 3-Dec-12 1-Jul-17 12.00 0.10 500 50,000 50,000 3-Dec-12 1-Jul-17 12.00 0.10 150 15,000 15,000 3-Dec-12 1-Jul-18 12.00 0.010 - 237 75,000 3-Dec-12 31-Mar-16 12.00 0.10 - - - 27-Mar-13 30-Sep-17 12.00 0.10 250 25,000 25,000 27-Mar-13 30-Sep-17 12.00 0.10 250 25,000 25,000 27-Mar-13 30-Sep-19 12.00 0.10 250 25,000 25,000 22-May-14 31-May-17 12.00 0.15 500 50,000 50,000 22-May-14 31-May-17 12.00 0.15 225 22,500 22,500 22-May-14 31-May-17 12.00 0.15 225 22,500 22,500 25-Aug-14 31-Jul-17 12.00 0.15 500 50,000 50,000 25-Aug-14 31-Jul-17 12.00 0.15 250 25,000 25,000 31-Oct-14 31-Oct-17 12.00 0.15 500 50,000 50,000 17-Feb-15 17-Feb-18 12.00 0.15 200 20,000 20,000 26-Mar-14 28-Feb-18 12.00 0.15 6,251 125,082 145,000 7-Jul-17 5-Jan-19 12.00 Variable - 183,600 - Total Face Value $ 2,447,919 $ 2,375,000 Unamortized Discount (327) (8,937) Total $ 2,447,592 $ 2,366,063 Following are maturities of the long –term debt as of September 30, 2017: Principal Payments 2017 $ 2,139,000 2018 100,319 2019 208,600 Total $ 2,447,919

Royalty Financing

Royalty Financing	9 Months Ended
	Sep. 30, 2017
Royalty Financing
Royalty Financing	Note 8. Royalty Financing On October 31, 2014, the Company entered into a royalty purchase agreement with Grenville Strategic Royalty Corp. (“Grenville”) for the amount of $2,000,000. The agreement calls for a monthly payment to Grenville based on a percentage of the total of certain revenue items and subject to a minimum payment amount until $8,000,000 has been paid. The amount financed is recorded net of discount to be amortized during the term. For the nine months ended September 30, 2017 and 2016, the Company has recorded discount amortization expense of $319,025 and $232,175, respectively. The balance as shown on the consolidated balance sheet as of September 30, 2017, was $2,326,448, net of $4,983,828 in unamortized discount. The balance as shown on the consolidated balance sheet as of December 31, 2016, was $2,007,424, net of $5,302,853 in unamortized discount. As of September 30, 2017, the Company paid a total of $689,723 in royalty payments. Additionally, the Company has accrued $609,986 in unpaid royalty fees from August 2016 to September 2017.

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2017
Related Party Transactions [Abstract]
Related Party Transactions	Note 9. Related Party Transactions During January 2015, the Company entered into an agreement with a Company that is owned and controlled by a major shareholder to provide consulting services. Fees payable for performance of the consulting services are $10,000 per month. In addition to the monthly fees, the consultant was paid at signing of the agreement, four million two hundred thousand (4,200,000) options to purchase common stock of the client at an exercise price of $0.15 per share with an expiry date of December 31, 2019.The options have a five (5) year term. Inputs used in Binomial Option Pricing model were as follow: stock price at grant date: $0.0517, exercise price $0.15, expected life of the option two and a half (2.5) years, volatility of 70%, and risk free rate of 0.03%. The options were recorded on the grant date at a value of $34,683. Fees incurred to the related party consultant for the nine months ended September 30, 2017 and 2016 were $90,000, respectively, and are included as an expense in Legal and Professional fees in the accompanying statement of operations for the period.

Common Stock Transactions

Common Stock Transactions	9 Months Ended
	Sep. 30, 2017
Equity [Abstract]
Common Stock Transactions	Note 10. Common Stock Transactions On August 24, 2017, 250,000 shares were issued for services valued at $23,750 based upon the closing price of the Company’s common stock at the grant date. On August 24, 2017, 1,600,000 shares of common stock were issued in exchange for $16,000 of a convertible note. On August 16, 2017, 1,500,000 shares of common stock were issued in exchange for $15,000 of a convertible note. On July 6, 2017, 1,400,000 shares of common stock were issued in exchange for $14,000 of a convertible note. On May 23, 2017, 1,240,000 shares of common stock were issued in exchange for $31,000 of a convertible note. On February 23, 2017, 765,000 shares were issued for services valued at $30,600 based upon the closing price of the Company’s common stock at the grant date. On November 28, 2016, 100,000 shares were issued for services valued at $9,000 based upon the closing price of the Company’s common stock at the grant date. On June 16, 2016, the Company issued 30,000 shares of common stock of the Company as part of the bridge convertible note to a private investor. The shares were valued at $609 based upon the closing price of the Company’s common stock at the grant date. On June 7, 2016, 50,000 shares were issued for services valued at $5,000 based upon the closing price of the Company’s common stock at the grant date. On March 22, 2016, the Company issued 70,000 shares of common stock of the Company as part of the bridge convertible note to a private investor. The shares were valued at $1,421 based upon the closing price of the Company’s common stock at the grant date. On February 18, 2016, the Company issued 100,000 shares of common stock of the Company as part of the bridge convertible note to a private investor. The shares were valued at $7,000 based upon the closing price of the Company’s common stock at the grant date.

Income Tax

Income Tax	9 Months Ended
	Sep. 30, 2017
Income Tax Disclosure [Abstract]
Income Tax	Note 11. Income Tax The Company follows ASC 740, Income Taxes The provisions of ASC 740 require companies to recognize in their financial statements the impact of a tax position if that position is more likely than not to be sustained upon audit, based upon the technical merits of the position. ASC 740 prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken on a tax return. ASC 740 also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods and disclosure. Management does not believe that the Company has any material uncertain tax positions requiring recognition or measurement in accordance with the provisions of ASC 740. Accordingly, the adoption of these provisions of ASC 740 did not have a material effect on the Company’s financial statements. The Company’s policy is to record interest and penalties on uncertain tax positions, if any, as income tax expense.

Going Concern

Going Concern	9 Months Ended
	Sep. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	Note. 12. Going Concern As shown in the accompanying consolidated financial statements, the Company incurred net comprehensive loss of $714,301, and $1,573,590 for the three and nine months ended September 30, 2017, respectively, as well as a working capital deficit of $6,237,521 at September 30, 2017. These conditions raise substantial doubt as to the Company’s ability to continue as a going concern. Management plans to raise additional financing in order to continue its operations and fulfill its debt obligations in 2017, but there can be no assurances that the plan will be successful. These consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2017
Subsequent Events [Abstract]
Subsequent Events	Note 13. Subsequent events The Company evaluated subsequent events through the date the consolidated financial statements were issued.

Accounting Policies (Policies)

Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2017
Accounting Policies [Abstract]
Organization and Basis of Presentation	Organization and Basis of Presentation Medical Imaging Corp., (“MIC” or the “Company”), a Nevada Corporation was incorporated in 2000. In 2005, the Company developed a business plan for private healthcare opportunities in Canada with the objective of owning and operating private diagnostic imaging clinics. In 2009, the Company purchased Canadian Teleradiology Services Inc., which operates as: Custom Teleradiology Services (“CTS”). CTS provides remote reading of medical diagnostic imaging scans for rural hospitals and clinics in Canada. In early 2010, the Company modified its business plan to grow its CTS subsidiary while commencing the acquisition of existing full service imaging clinics located in the United States and exploring the development of new diagnostic imaging technology. In 2012, the Company purchased Schuylkill Open MRI Inc., which operates as: Schuylkill Medical Imaging (“SMI”), an independent diagnostic imaging facility located in Pottsville, Pennsylvania. In 2014, the Company purchased Partners Imaging Center of Venice, LLC (“PIV”) located in Venice, Florida; Partners Imaging Center of Naples, LLC (“PIN”) located in Naples, Florida; and Partners Imaging Center of Charlotte, LLC (“PIC”) located in Port Charlotte, Florida. Basis of Presentation These consolidated financial statements and related notes are presented in accordance with accounting principles generally accepted in the United States, and are expressed in U.S. dollars. The Company’s fiscal year-end is December 31.
Principle of Consolidation	Principle of Consolidation The consolidated financial statements include the accounts of Medical Imaging, Corp., and its wholly-owned subsidiaries, CTS, SMI, PIV, PIN, and PIC. Intercompany accounts and transactions have been eliminated in the consolidated financial statements. CTS’, SMI’s, PIV’s, PIN’s, and PIC’s accumulated earnings prior to their acquisitions are not included in the consolidated balance sheet.
Use of Estimates and Assumptions	Use of Estimates and Assumptions The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) requires management to make estimates and assumptions that affect (i) the reported amounts of assets and liabilities, (ii) the disclosure of contingent assets and liabilities known to exist as of the date the consolidated financial statements are published, and (iii) the reported amount of net sales, expenses and costs recognized during the periods presented. Adjustments made with respect to the use of estimates often relate to improved information not previously available. Uncertainties with respect to such estimates and assumptions are inherent in the preparation of consolidated financial statements; accordingly, actual results could differ from these estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. At September 30, 2017, and December 31, 2016, cash includes cash on hand and cash in the bank.
Accounts Receivable Credit Risk	Accounts Receivable Credit Risk The allowance for doubtful accounts is maintained at a level sufficient to provide for estimated credit losses based on evaluating known and inherent risks in the receivables portfolio. Management evaluates various factors including expected losses and economic conditions to predict the estimated realization on outstanding receivables. In connection with the acquisition of the three facilities located in Venice, Port Charlotte and Naples, Florida, the Company, in October 2014, entered into professional services agreements whereby the seller of those three facilities continued to handle the billing and collection for the imaging centers (the “third party billing”). The seller must still provide a full set of verification data to the Company with respect to its account receivable processing and collections so that the Company can determine the extent to which accounts submitted by the seller in connection with the third party billing have been collected or denied. Final verification will only be able to be completed after the conclusion of the services performed pursuant to the third party billing contract, and review of account balances which is expected during the 2017 fiscal year. Although the gross receivable balance has increased significantly, management is actively pursuing collection efforts directly with patients and insurance payers and believes that the current allowance for doubtful accounts is sufficient to cover any expected losses.
Goodwill and Indefinite Intangible Assets	Goodwill and Indefinite - Lived Intangible Assets The Company follows the provisions of Financial Accounting Standard Accounting Standards Codification (“ASC”) 350, Goodwill and Other Intangible Assets
Revenue Recognition	Revenue Recognition The Company holds contracts with several hospitals and groups of health care facilities to provide Teleradiology services for a specific period of time. The Company bills for services rendered on a monthly basis. For the three and nine months ended September 30, 2017, CTS held six contracts; four contracts that are renewable on a year-to-year basis and one contract that automatically renewed in 2016 for a successive one year term, and one to be renewed in 2018. In accordance with the requirement of Staff Accounting Bulletin (“SAB”) 104, the Company recognizes revenue when: (1) persuasive evidence of an arrangement exists (contracts); (2) delivery has occurred (monthly); (3) the seller’s price is fixed or determinable (per the customer’s contract, and services performed); and (4) collectability is reasonably assured (based upon our credit policy). Revenue is accounted for under the guidelines established by SAB 101, Revenue Recognition in Financial Statements, Revenue Recognition
Cost of Sales	Cost of Sales Cost of sales includes fees paid to radiologists for reading services, transcription fees, equipment repairs, system license and usage costs.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets In accordance with ASC 360, Property, Plant and Equipment, Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset.
Convertible Debentures	Convertible Debentures Debt – Debt with Conversion and Other Options The Company accounts for modifications of its Embedded Conversion Features in accordance with ASC 470-50, Debt – Modifications and Exchanges, , Debt – Modification and Exchanges – Extinguishment of Debt
Stock Based Compensation	Stock Based Compensation The Company follows ASC 718, Stock Compensation The Company measures all share-based payments to employees (which includes non-employee Board of Directors), including employee stock options, warrants and restricted stock, at the fair value of the award and expenses it over the requisite service period (generally the vesting period). The fair value of common stock options or warrants granted to employees is estimated at the date of grant using the binomial option pricing model (“BOPM”). The calculation also takes into account the common stock fair market value at the grant date, the exercise price, the expected life of the common stock option or warrant, the dividend yield and the risk-free interest rate. The Company from time to time may issue stock options, warrants and restricted stock to acquire goods or services from third parties. Restricted stock, options or warrants issued to other than employees or directors are recorded on the basis of their fair value. The options or warrants are valued using the BOPM on the basis of the market price of the underlying equity instrument on the “valuation date,” which for options and warrants related to contracts that have substantial disincentives to non-performance, is the date of the contract, and for all other contracts is the vesting date. Expenses related to the options and warrants are recognized on a straight-line basis over the period which services are to be received.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The fair value of a financial instrument is the amount at which the instrument could be exchanged in a current transaction between willing parties other than in a forced sale or liquidation. The carrying amounts of the Company’s financial instruments, including cash, accounts receivable, prepaid expenses, accounts payable, accrued liabilities and notes and loans payable approximate fair value due to their most maturities.
Fair Value Measurements	Fair Value Measurements The Company follows ASC 820, Fair Value Measurements and Disclosures Level 1 Quoted market prices available in active markets for identical assets or liabilities as of the reporting date. Level 2 pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date. Level 3 pricing inputs that are generally observable inputs and not corroborated by market data. The carrying amounts of the Company’s financial assets and liabilities, such as cash and accounts payable approximate their fair values because of the short maturity of these instruments. The Company does not have assets and liabilities that are carried at fair value on a recurring basis.
Foreign Currency Translation	Foreign Currency Translation The Company’s functional currency for its wholly-owned subsidiary, CTS, is the Canadian dollar, and their financial statements have been translated into U.S. dollars. The Canadian dollar based accounts of the Company’s foreign operations have been translated into United States dollars using the current rate method. Assets and liabilities of those operations are translated into U.S. dollars using exchange rates as of the balance sheet date; income and expenses are translated using the weighted average exchange rates for the reporting period. Translation adjustments are recorded as accumulated other comprehensive income (loss), a separate component of stockholders’ equity.
Income Taxes	Income Taxes The Company accounts for income taxes in accordance with ASC 740, Income Taxes
Net Income (Loss) Per Share	Net Income (Loss) Per Share The Company follows the provisions of ASC 260, Earnings per Share Basic earnings per share is computed by dividing net income available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share reflects the potential dilution that could occur if stock options and other commitments to issue common stock were exercised or equity awards vest resulting in the issuance of common stock or conversion of notes into shares of the Company’s common stock that could increase the number of shares outstanding and lower the earnings per share of the Company’s common stock. This calculation is not done for periods in a loss position as this would be antidilutive.
Recent Accounting Updates	Recent Accounting Updates The Company does not expect the adoption of any recently issued accounting pronouncements to have a significant impact on its results of operations, financial position or cash flow.

Property and Equipment (Tables)

Property and Equipment (Tables)	9 Months Ended
	Sep. 30, 2017
Property, Plant and Equipment [Abstract]
Property Plant and Equipment	September 30, 2017 December 31, 2016 Estimated useful lives Computer/Office Equipment $ 529,851 $ 474,887 3-7 years Medical Equipment 2,301,351 2,329,872 3-7 years Leasehold Improvements 870,980 857,770 5-39 years Less: Accumulated Depreciation (1,900,916) (1,562,471) Net Book Value $ 1,801,266 $ 2,100,058

Operating Lease Commitments (Ta

Operating Lease Commitments (Tables)	9 Months Ended
	Sep. 30, 2017
Leases, Operating [Abstract]
Schedule of Operating Lease Commitments	Year Total 2017 $ 101,979 2018 435,062 2019 430,599 2020 355,177 2021 217,263 Thereafter - $ 1,540,080

Capital Lease Obligations (Tabl

Capital Lease Obligations (Tables)	9 Months Ended
	Sep. 30, 2017
Leases, Capital [Abstract]
Schedule of Capital Leased Obligations	Description Monthly payments Maturity Date APR * September 30, 2017 Balance December 31, 2016 Balance SMI X-Ray Machine $ 1,495 15-Aug-19 6.32 % $ 32,312 $ 43,930 SMI PACS/RIS System 3,115 1-Nov-19 5.69 76,028 100,240 SMI Copier 135 1-Aug-18 27.63 1,299 2,144 SMI Ascentrium 2,450 18-Nov-18 21.48 28,830 44,776 PIV,PIN,PIC PACS/RIS 3,094 1-Jan-20 4.22 82,368 107,170 PIV,PIN,PIC Computers 813 1-Nov-17 10.52 1,612 8,509 PIV,PIN,PIC Digital Printers 423 24-Feb-19 9.90 6,680 9,856 CTS Computers 554 2-Feb-18 2.25 2,915 7,649 PIN CT Lease 2,332 1-Aug-19 0 % 53,635 Total $ 14,411 $ 285,679 $ 324,274
Schedule of Future Minimum Lease Payments for Capital Leases	Minimum Lease Payments Total 2017 $ 42,517 2018 153,079 2019 102,857 2020 3,094 Total minimum lease payments 301,547 Less amount representing interest 15,868 Present value of minimum lease payments 285,679 Less current portion of minimum lease payments 148,675 Long-term capital lease obligations at September 30, 2017 $ 137,004

Promissory Notes (Tables)

Promissory Notes (Tables)	9 Months Ended
	Sep. 30, 2017
Debt Disclosure [Abstract]
Schedule of Promissory Notes	Issuance Date Maturity Date APR 1 Payment Amount Payments Frequency September 30, 2017 Face Value Balance December 31, 2016 Face Value Balance 16-Feb-16 23-Feb-17 2 12.00 % $ 1,000 Monthly $ 100,000 $ 100,000 22-Feb-16 31-Aug-17 2 25.00 10,417 Monthly 500,000 500,000 22-Mar-16 22-Mar-17 2 12.00 700 Monthly 70,000 70,000 1-Jul-16 1-Aug-17 2 20.00 20,000 Monthly 280,000 400,000 3-Oct-16 27-Dec-17 42.09 2,255 Weekly - 117,261 18-May-17 1-Jul-19 3 20.00 $ 15,000 Monthly* 165,000 - 28-Jul-17 26-Jul-18 39.00 1,419 Daily 233,151 - 7-Aug-17 16-Oct-18 33.00 213 Daily 55,754 - 8-Sep-17 30-Mar-18 19.00 % 3,667 Weekly 92,415 - Total Face Value 1,436,320 1,187,261 Unamortized Discount (201,624) (143,419) Total $ 1,234,696 $ 1,043,842 1 2 3
Schedule of Promissory Notes Debt Maturities	Principal Payments 2017 $ 860,244 2018 471,076 2019 105,000 Total $ 1,436,320

Convertible Notes (Tables)

Convertible Notes (Tables)	9 Months Ended
	Sep. 30, 2017
Debt Disclosure [Abstract]
Schedule of Convertible Debt	Issuance Date Maturity Date APR Conversion Rate Monthly Payment September 30, 2017 Face Value Balance December 31, 2016 Face Value Balance 3-Dec-12 1-Jul-17 12.00 % $ 0.10 $ 250 $ 25,000 $ 25,000 27-Mar-13 1-Jul-17 12.00 0.10 750 75,000 75,000 3-Dec-12 1-Jul-17 12.00 0.10 250 50,000 50,000 3-Dec-12 1-Jul-17 12.00 0.10 340 34,000 50,000 3-Dec-12 1-Jul-17 12.00 0.10 250 25,000 25,000 3-Dec-12 1-Jul-17 12.00 0.10 250 25,000 25,000 3-Dec-12 1-Jul-17 12.00 0.10 250 25,000 25,000 3-Dec-12 1-Jul-17 12.00 0.10 15,000 1,500,000 1,500,000 3-Dec-12 1-Jul-17 12.00 0.10 500 50,000 50,000 3-Dec-12 1-Jul-17 12.00 0.10 150 15,000 15,000 3-Dec-12 1-Jul-18 12.00 0.010 - 237 75,000 3-Dec-12 31-Mar-16 12.00 0.10 - - - 27-Mar-13 30-Sep-17 12.00 0.10 250 25,000 25,000 27-Mar-13 30-Sep-17 12.00 0.10 250 25,000 25,000 27-Mar-13 30-Sep-19 12.00 0.10 250 25,000 25,000 22-May-14 31-May-17 12.00 0.15 500 50,000 50,000 22-May-14 31-May-17 12.00 0.15 225 22,500 22,500 22-May-14 31-May-17 12.00 0.15 225 22,500 22,500 25-Aug-14 31-Jul-17 12.00 0.15 500 50,000 50,000 25-Aug-14 31-Jul-17 12.00 0.15 250 25,000 25,000 31-Oct-14 31-Oct-17 12.00 0.15 500 50,000 50,000 17-Feb-15 17-Feb-18 12.00 0.15 200 20,000 20,000 26-Mar-14 28-Feb-18 12.00 0.15 6,251 125,082 145,000 7-Jul-17 5-Jan-19 12.00 Variable - 183,600 - Total Face Value $ 2,447,919 $ 2,375,000 Unamortized Discount (327) (8,937) Total $ 2,447,592 $ 2,366,063
Schedule of Maturities of Long-term Debt	Principal Payments 2017 $ 2,139,000 2018 100,319 2019 208,600 Total $ 2,447,919

Organization and Summary of S25

Organization and Summary of Significant Accounting Policies (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Accounts Receivable, Net, Current
Allowance for doubtful accounts	$ 299,545		$ 299,545		$ 200,982
Allowance for Doubtful Accounts - Third Party Billings (Florida Operations)	275,000		275,000		$ 275,000
Foreign Currency Translation
Foreign currency gain (loss)	(11,438)	$ (595)	(74,140)	$ (39,846)
Other comprehensive income (loss)	(12,495)	28,738	42,317	96,917
Employee Stock
Recognized Share-Based Compensation Expense
Stock-based compensation expense	$ 23,750	$ 0	30,600	$ 5,000
Employee Stock Option
Recognized Share-Based Compensation Expense
Stock-based compensation expense			$ 8,500

Property and Equipment (Details

Property and Equipment (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2017	Dec. 31, 2016
Property, Plant and Equipment [Line Items]
Property and equipment, accumulated depreciation	$ (1,900,916)	$ (1,562,471)
Property and equipment, net	1,801,266	2,100,058
Computer/Office Equipment
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 529,851	$ 474,887
Property and equipment, estimated useful lives	3-7 years	3-7 years
Medical Equipment
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 2,301,351	$ 2,329,872
Property and equipment, estimated useful lives	3-7 years	3-7 years
Leasehold Improvements
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 870,980	$ 857,770
Property and equipment, estimated useful lives	5-39 years	5-39 years

Property and Equipment (Detai27

Property and Equipment (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Depreciation expense	$ 144,604	$ 140,550	$ 440,469	$ 418,298
Equipment purchase			184,339	$ 102,847
Asset impairment charges			206,420
Equipment
Equipment purchase			201,463
Leasehold Improvements
Equipment purchase			12,639
Computer/Office Equipment
Equipment purchase			$ 26,205

Operating Lease Commitments (De

Operating Lease Commitments (Details)	Sep. 30, 2017USD ($)
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity
Year 2,017	$ 101,979
Year 2,018	435,062
Year 2,019	430,599
Year 2,020	355,177
Year 2,021	217,263
Thereafter	0
Operating Leases, Future Minimum Payments Due	$ 1,540,080

Operating Lease Commitments (29

Operating Lease Commitments (Details Narrative)	9 Months Ended
	Sep. 30, 2017USD ($)
CTS - Office Space
Operating lease, minimum payments	$ 2,450
Leasing arrangements	CTS has a lease commitment for a period of five years and will expire in March 2018.
Loss on sublease	$ 8,000
CTS - Office Space - Toronto, Canada
Operating lease, minimum payments	$ 2,600
Leasing arrangements	CTS has a lease commitment for its new office space in Toronto, Canada and the lease will expire April 30, 2021.
SMI - Office Space - Pottsville, Pennsylvania
Operating lease, minimum payments	$ 6,908
Leasing arrangements	SMI entered into a lease commitment for its office space in Pottsville, Pennsylvania and the lease will expire on July 30, 2021.
SMI - X-Ray Equipment
Operating lease, minimum payments	$ 3,000
Leasing arrangements	Lease for x-ray equipment space. The lease term is seven years from commitment date of October 2014.
SMI - X-Ray Equipment #2
Operating lease, minimum payments	$ 2,000
Leasing arrangements	Lease for use of x-ray equipment and space. The lease term is two years from commitment date of January 2016.
Lease Arrangement | PIC
Operating lease, minimum payments	$ 5,512
Leasing arrangements	PIC has a lease for office space in Port Charlotte, Florida. The lease will expire June 20, 2021.
Lease Arrangement | PIN
Operating lease, minimum payments	$ 9,543
Leasing arrangements	PIN has a lease for office space in Naples, Florida. The lease will expire January 1, 2020.
Lease Arrangement | PIV
Operating lease, minimum payments	$ 13,170
Leasing arrangements	PIV has a lease for office space in Venice, Florida. The lease will expire September 30, 2021.

Capital Lease Obligations - Sch

Capital Lease Obligations - Schedule of Capital Lease Obligations (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2017	Dec. 31, 2016
Capital Leased Assets [Line Items]
Capital lease obligation	$ 285,679	$ 324,274
Capital lease, monthly payments	14,411	14,411
SMI - X-Ray Lease
Capital Leased Assets [Line Items]
Capital lease obligation	32,312	43,930
Capital lease, monthly payments	$ 1,495	$ 1,495
Capital lease, maturity date	Aug. 15, 2019	Aug. 15, 2019
Capital lease, annual percentage rate	6.32%	6.32%
SMI - PACS/RIS Lease
Capital Leased Assets [Line Items]
Capital lease obligation	$ 76,028	$ 100,240
Capital lease, monthly payments	$ 3,115	$ 3,115
Capital lease, maturity date	Nov. 1, 2019	Nov. 1, 2019
Capital lease, annual percentage rate	5.69%	5.69%
SMI Copier Lease
Capital Leased Assets [Line Items]
Capital lease obligation	$ 1,299	$ 2,144
Capital lease, monthly payments	$ 135	$ 135
Capital lease, maturity date	Aug. 1, 2018	Aug. 1, 2018
Capital lease, annual percentage rate	27.63%	27.63%
SMI Ascentrium
Capital Leased Assets [Line Items]
Capital lease obligation	$ 28,830	$ 44,776
Capital lease, monthly payments	$ 2,450	$ 2,450
Capital lease, maturity date	Nov. 18, 2018	Nov. 18, 2018
Capital lease, annual percentage rate	21.48%	21.48%
PV, PN, PC PACS/RIS Lease
Capital Leased Assets [Line Items]
Capital lease obligation	$ 82,368	$ 107,170
Capital lease, monthly payments	$ 3,094	$ 3,094
Capital lease, maturity date	Jan. 1, 2020	Jan. 1, 2020
Capital lease, annual percentage rate	4.22%	4.22%
PV, PN, PC Computers Lease
Capital Leased Assets [Line Items]
Capital lease obligation	$ 1,612	$ 8,509
Capital lease, monthly payments	$ 813	$ 813
Capital lease, maturity date	Nov. 1, 2017	Nov. 1, 2017
Capital lease, annual percentage rate	10.52%	10.52%
PV, PN, PC Digital Printers Lease
Capital Leased Assets [Line Items]
Capital lease obligation	$ 6,680	$ 9,856
Capital lease, monthly payments	$ 423	$ 423
Capital lease, maturity date	Feb. 24, 2019	Feb. 24, 2019
Capital lease, annual percentage rate	9.90%	9.90%
CTS Computers Lease
Capital Leased Assets [Line Items]
Capital lease obligation	$ 2,915	$ 7,649
Capital lease, monthly payments	$ 554	$ 554
Capital lease, maturity date	Feb. 2, 2018	Feb. 2, 2018
Capital lease, annual percentage rate	2.25%	2.25%
PIN CT Lease
Capital Leased Assets [Line Items]
Capital lease obligation	$ 53,635	$ 0
Capital lease, monthly payments	$ 2,332
Capital lease, maturity date	Aug. 1, 2019
Capital lease, annual percentage rate	0.00%

Capital Lease Obligations - S31

Capital Lease Obligations - Schedule of Future Minimum Lease Payments (Details) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Capital Leases Future Minimum Payments
Minimum lease payments, 2017	$ 42,517
Minimum lease payments, 2018	153,079
Minimum lease payments, 2019	102,857
Minimum lease payments, 2020	3,094
Total minimum lease payments	301,547
Less amount representing interest	15,868
Present value of minimum lease payments	285,679
Less current portion of minimum lease payments	148,675	$ 123,738
Long-term Capital Lease Obligations at June 30, 2017	$ 137,004	$ 200,536

Promissory Notes - Schedule of

Promissory Notes - Schedule of Promissory Notes (Details) - USD ($)		9 Months Ended	12 Months Ended
		Sep. 30, 2017	Dec. 31, 2016
Short-term Debt [Line Items]
Promissory notes, balance		$ 1,436,320	$ 1,187,261
Unamortized Discount		$ (201,624)	$ (143,419)
Promissory Note #1
Short-term Debt [Line Items]
Promissory note, issuance date		Feb. 16, 2016	Feb. 16, 2016
Promissory note, maturity date	[1]	Feb. 23, 2017	Feb. 23, 2017
Promissory note, interest rate	[2]	12.00%	12.00%
Promissory notes, payments		$ 1,000	$ 1,000
Promissory notes, payment frequency		Monthly	Monthly
Promissory notes, balance		$ 100,000	$ 100,000
Promissory Note #2
Short-term Debt [Line Items]
Promissory note, issuance date		Feb. 22, 2016	Feb. 22, 2016
Promissory note, maturity date	[1]	Aug. 31, 2017	Aug. 31, 2017
Promissory note, interest rate	[2]	25.00%	25.00%
Promissory notes, payments		$ 10,417	$ 10,417
Promissory notes, payment frequency		Monthly	Monthly
Promissory notes, balance		$ 500,000	$ 500,000
Promissory Note #3
Short-term Debt [Line Items]
Promissory note, issuance date		Mar. 22, 2016	Mar. 22, 2016
Promissory note, maturity date	[1]	Mar. 22, 2017	Mar. 22, 2017
Promissory note, interest rate	[2]	12.00%	12.00%
Promissory notes, payments		$ 700	$ 700
Promissory notes, payment frequency		Monthly	Monthly
Promissory notes, balance		$ 70,000	$ 70,000
Promissory Note #4
Short-term Debt [Line Items]
Promissory note, issuance date		Jul. 1, 2016	Jul. 1, 2016
Promissory note, maturity date	[1]	Aug. 1, 2017	Aug. 1, 2017
Promissory note, interest rate	[2]	20.00%	20.00%
Promissory notes, payments		$ 20,000	$ 20,000
Promissory notes, payment frequency		Monthly	Monthly
Promissory notes, balance		$ 220,000	$ 400,000
Promissory Note #5
Short-term Debt [Line Items]
Promissory note, issuance date		Oct. 3, 2016	Oct. 3, 2016
Promissory note, maturity date		Dec. 27, 2017	Dec. 27, 2017
Promissory note, interest rate	[2]	42.09%	42.09%
Promissory notes, payments		$ 2,255	$ 2,255
Promissory notes, payment frequency		Weekly	Weekly
Promissory notes, balance		$ 0	$ 117,261
Promissory Note #6
Short-term Debt [Line Items]
Promissory note, issuance date		May 18, 2017
Promissory note, maturity date	[3]	Jul. 1, 2019
Promissory note, interest rate	[2]	20.00%
Promissory notes, payments		$ 15,000
Promissory notes, payment frequency		Monthly
Promissory notes, balance		$ 165,000
Promissory Note #7
Short-term Debt [Line Items]
Promissory note, issuance date		Jul. 28, 2017
Promissory note, maturity date		Jul. 26, 2018
Promissory note, interest rate	[2]	39.00%
Promissory notes, payments		$ 1,419
Promissory notes, payment frequency		Daily
Promissory notes, balance		$ 233,151
Promissory Note #8
Short-term Debt [Line Items]
Promissory note, issuance date		Aug. 7, 2017
Promissory note, maturity date		Oct. 16, 2018
Promissory note, interest rate		33.00%
Promissory notes, payments		$ 213
Promissory notes, payment frequency		Daily
Promissory notes, balance		$ 55,754
Promissory Note #9
Short-term Debt [Line Items]
Promissory note, issuance date		Sep. 8, 2017
Promissory note, maturity date		Mar. 30, 2018
Promissory note, interest rate		19.00%
Promissory notes, payments		$ 3,667
Promissory notes, payment frequency		Weekly
Promissory notes, balance		$ 92,415
[1]	Principal Overdue
[2]	Imputed Annual Percentage Rate ("APR")
[3]	Scheduled monthly payments of $15,000 for promissory note issued on May 18, 2017 will begin September 1, 2018.

Promissory Notes - Schedule o33

Promissory Notes - Schedule of Promissory Notes Debt Maturities (Details) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Debt Disclosure [Abstract]
2,017	$ 860,244
2,018	471,076
2,019	105,000
Total	$ 1,436,320	$ 1,187,261

Convertible Notes - Schedule of

Convertible Notes - Schedule of Convertible Debt (Details) - USD ($)	9 Months Ended		12 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Debt Instrument [Line Items]
Convertible note, monthly payment	$ 35,000	$ 5,000
Convertible Note
Debt Instrument [Line Items]
Convertible note, balance	$ 2,447,592		$ 2,366,063
Convertible Note | Note #8
Debt Instrument [Line Items]
Convertible note, issuance date	Dec. 3, 2012		Dec. 3, 2012
Convertible note, maturity date	Jul. 1, 2017		Jul. 1, 2017
Convertible note, interest rate	12.00%		12.00%
Convertible note, conversion rate	$ 0.10		$ 0.10
Convertible note, monthly payment	$ 15,000		$ 15,000
Convertible note, balance	$ 1,500,000		$ 1,500,000
Convertible Note | Note #7
Debt Instrument [Line Items]
Convertible note, issuance date	Dec. 3, 2012		Dec. 3, 2012
Convertible note, maturity date	Jul. 1, 2017		Jul. 1, 2017
Convertible note, interest rate	12.00%		12.00%
Convertible note, conversion rate	$ 0.10		$ 0.10
Convertible note, monthly payment	$ 250		$ 250
Convertible note, balance	$ 25,000		$ 25,000
Convertible Note | Note #6
Debt Instrument [Line Items]
Convertible note, issuance date	Dec. 3, 2012		Dec. 3, 2012
Convertible note, maturity date	Jul. 1, 2017		Jul. 1, 2017
Convertible note, interest rate	12.00%		12.00%
Convertible note, conversion rate	$ 0.10		$ 0.10
Convertible note, monthly payment	$ 250		$ 250
Convertible note, balance	$ 25,000		$ 25,000
Convertible Note | Note #5
Debt Instrument [Line Items]
Convertible note, issuance date	Dec. 3, 2012		Dec. 3, 2012
Convertible note, maturity date	Jul. 1, 2017		Jul. 1, 2017
Convertible note, interest rate	12.00%		12.00%
Convertible note, conversion rate	$ 0.10		$ 0.10
Convertible note, monthly payment	$ 250		$ 250
Convertible note, balance	$ 25,000		$ 25,000
Convertible Note | Note #4
Debt Instrument [Line Items]
Convertible note, issuance date	Dec. 3, 2012		Dec. 3, 2012
Convertible note, maturity date	Jul. 1, 2017		Jul. 1, 2017
Convertible note, interest rate	12.00%		12.00%
Convertible note, conversion rate	$ 0.10		$ 0.10
Convertible note, monthly payment	$ 340		$ 340
Convertible note, balance	$ 34,000		$ 50,000
Convertible Note | Note #3
Debt Instrument [Line Items]
Convertible note, issuance date	Dec. 3, 2012		Dec. 3, 2012
Convertible note, maturity date	Jul. 1, 2017		Jul. 1, 2017
Convertible note, interest rate	12.00%		12.00%
Convertible note, conversion rate	$ 0.10		$ 0.10
Convertible note, monthly payment	$ 250		$ 250
Convertible note, balance	$ 50,000		$ 50,000
Convertible Note | Note #2
Debt Instrument [Line Items]
Convertible note, issuance date	Mar. 27, 2013		Mar. 27, 2013
Convertible note, maturity date	Jul. 1, 2017		Jul. 1, 2017
Convertible note, interest rate	12.00%		12.00%
Convertible note, conversion rate	$ 0.10		$ 0.10
Convertible note, monthly payment	$ 750		$ 750
Convertible note, balance	$ 75,000		$ 75,000
Convertible Note | Note #1
Debt Instrument [Line Items]
Convertible note, issuance date	Dec. 3, 2012		Dec. 3, 2012
Convertible note, maturity date	Jul. 1, 2017		Jul. 1, 2017
Convertible note, interest rate	12.00%		12.00%
Convertible note, conversion rate	$ 0.10		$ 0.10
Convertible note, monthly payment	$ 250		$ 250
Convertible note, balance	$ 25,000		$ 25,000

Convertible Notes - Schedule 35

Convertible Notes - Schedule of Convertible Debt, Continued #2 (Details) - USD ($)	9 Months Ended		12 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Debt Instrument [Line Items]
Convertible note, monthly payment	$ 35,000	$ 5,000
Convertible Note
Debt Instrument [Line Items]
Convertible note, balance	$ 2,447,919		$ 2,375,000
Convertible Note | Note #16
Debt Instrument [Line Items]
Convertible note, issuance date	May 22, 2014		May 22, 2014
Convertible note, maturity date	May 31, 2017		May 31, 2017
Convertible note, interest rate	12.00%		12.00%
Convertible note, conversion rate	$ 0.15		$ 0.15
Convertible note, monthly payment	$ 500		$ 500
Convertible note, balance	$ 50,000		$ 50,000
Convertible Note | Note #15
Debt Instrument [Line Items]
Convertible note, issuance date	Mar. 27, 2013		Mar. 27, 2016
Convertible note, maturity date	Sep. 30, 2019		Sep. 30, 2019
Convertible note, interest rate	12.00%		12.00%
Convertible note, conversion rate	$ 0.10		$ 0.15
Convertible note, monthly payment	$ 250		$ 250
Convertible note, balance	$ 25,000		$ 25,000
Convertible Note | Note #14
Debt Instrument [Line Items]
Convertible note, issuance date	Mar. 27, 2013		Mar. 27, 2013
Convertible note, maturity date	Sep. 30, 2017		Sep. 30, 2017
Convertible note, interest rate	12.00%		12.00%
Convertible note, conversion rate	$ 0.10		$ 0.10
Convertible note, monthly payment	$ 250		$ 250
Convertible note, balance	$ 25,000		$ 25,000
Convertible Note | Note #13
Debt Instrument [Line Items]
Convertible note, issuance date	Mar. 27, 2013		Mar. 27, 2013
Convertible note, maturity date	Sep. 30, 2017		Sep. 30, 2017
Convertible note, interest rate	12.00%		12.00%
Convertible note, conversion rate	$ 0.10		$ 0.10
Convertible note, monthly payment	$ 250		$ 250
Convertible note, balance	$ 25,000		$ 25,000
Convertible Note | Note #12
Debt Instrument [Line Items]
Convertible note, issuance date	Dec. 3, 2012		Dec. 3, 2012
Convertible note, maturity date	Mar. 31, 2016		Mar. 31, 2016
Convertible note, interest rate	12.00%		12.00%
Convertible note, conversion rate	$ 0.10		$ 0.10
Convertible note, monthly payment	$ 0		$ 0
Convertible note, balance	$ 0		$ 0
Convertible Note | Note #11
Debt Instrument [Line Items]
Convertible note, issuance date	Dec. 3, 2012		Dec. 3, 2012
Convertible note, maturity date	Jul. 1, 2018		Jul. 1, 2018
Convertible note, interest rate	12.00%		12.00%
Convertible note, conversion rate	$ 0.010		$ 0.025
Convertible note, monthly payment	$ 0		$ 0
Convertible note, balance	$ 237		$ 75,000
Convertible Note | Note #10
Debt Instrument [Line Items]
Convertible note, issuance date	Dec. 3, 2012		Dec. 3, 2012
Convertible note, maturity date	Jul. 1, 2017		Jul. 1, 2017
Convertible note, interest rate	12.00%		12.00%
Convertible note, conversion rate	$ 0.10		$ 0.10
Convertible note, monthly payment	$ 150		$ 150
Convertible note, balance	$ 15,000		$ 15,000
Convertible Note | Note #9
Debt Instrument [Line Items]
Convertible note, issuance date	Dec. 3, 2012		Dec. 3, 2012
Convertible note, maturity date	Jul. 1, 2017		Jul. 1, 2017
Convertible note, interest rate	12.00%		12.00%
Convertible note, conversion rate	$ 0.10		$ 0.10
Convertible note, monthly payment	$ 500		$ 500
Convertible note, balance	$ 50,000		$ 50,000

Convertible Notes - Schedule 36

Convertible Notes - Schedule of Convertible Debt, Continued #3 (Details) - USD ($)	9 Months Ended		12 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Debt Instrument [Line Items]
Convertible note, monthly payment	$ 35,000	$ 5,000
Convertible note, unamortized debt discount	(201,624)		$ (143,419)
Convertible Note
Debt Instrument [Line Items]
Convertible note, balance	2,447,919		2,375,000
Convertible note, unamortized debt discount	(327)		(8,937)
Convertible note, total	$ 2,447,592		$ 2,366,063
Convertible Note | Note #24
Debt Instrument [Line Items]
Convertible note, issuance date	Jul. 7, 2017
Convertible note, maturity date	Jan. 5, 2019
Convertible note, interest rate	12.00%
Convertible note, monthly payment	$ 0
Convertible note, balance	$ 183,600
Convertible Note | Note #23
Debt Instrument [Line Items]
Convertible note, issuance date	Mar. 26, 2014		Mar. 26, 2014
Convertible note, maturity date	Feb. 28, 2018		Feb. 28, 2018
Convertible note, interest rate	12.00%		12.00%
Convertible note, conversion rate	$ 0.15		$ 0.15
Convertible note, monthly payment	$ 6,251		$ 6,251
Convertible note, balance	$ 125,082		$ 145,000
Convertible Note | Note #22
Debt Instrument [Line Items]
Convertible note, issuance date	Feb. 17, 2015		Feb. 17, 2015
Convertible note, maturity date	Feb. 17, 2018		Feb. 17, 2018
Convertible note, interest rate	12.00%		12.00%
Convertible note, conversion rate	$ 0.15		$ 0.15
Convertible note, monthly payment	$ 200		$ 200
Convertible note, balance	$ 20,000		$ 20,000
Convertible Note | Note #21
Debt Instrument [Line Items]
Convertible note, issuance date	Oct. 31, 2014		Oct. 31, 2014
Convertible note, maturity date	Oct. 31, 2017		Oct. 31, 2017
Convertible note, interest rate	12.00%		12.00%
Convertible note, conversion rate	$ 0.15		$ 0.15
Convertible note, monthly payment	$ 500		$ 500
Convertible note, balance	$ 50,000		$ 50,000
Convertible Note | Note #20
Debt Instrument [Line Items]
Convertible note, issuance date	Aug. 14, 2014		Aug. 14, 2014
Convertible note, maturity date	Jul. 31, 2017		Jul. 31, 2017
Convertible note, interest rate	12.00%		12.00%
Convertible note, conversion rate	$ 0.15		$ 0.15
Convertible note, monthly payment	$ 250		$ 250
Convertible note, balance	$ 25,000		$ 25,000
Convertible Note | Note #19
Debt Instrument [Line Items]
Convertible note, issuance date	Aug. 25, 2014		Aug. 25, 2014
Convertible note, maturity date	Jul. 31, 2017		Jul. 31, 2017
Convertible note, interest rate	12.00%		12.00%
Convertible note, conversion rate	$ 0.15		$ 0.15
Convertible note, monthly payment	$ 500		$ 500
Convertible note, balance	$ 50,000		$ 50,000
Convertible Note | Note #18
Debt Instrument [Line Items]
Convertible note, issuance date	May 22, 2014		May 22, 2014
Convertible note, maturity date	May 31, 2017		May 31, 2017
Convertible note, interest rate	12.00%		12.00%
Convertible note, conversion rate	$ 0.15		$ 0.15
Convertible note, monthly payment	$ 225		$ 225
Convertible note, balance	$ 22,500		$ 22,500
Convertible Note | Note #17
Debt Instrument [Line Items]
Convertible note, issuance date	May 22, 2014		May 22, 2014
Convertible note, maturity date	May 31, 2017		May 31, 2017
Convertible note, interest rate	12.00%		12.00%
Convertible note, conversion rate	$ 0.15		$ 0.15
Convertible note, monthly payment	$ 225		$ 225
Convertible note, balance	$ 22,500		$ 22,500

Convertible Notes - Schedule 37

Convertible Notes - Schedule of Long-Term Debt Maturities (Details)	Sep. 30, 2017USD ($)
Debt Disclosure [Abstract]
Principal payments, 2017	$ 2,139,000
Principal payments, 2018	100,319
Principal payments, 2019	208,600
Total principal payments	$ 2,447,919

Convertible Notes (Details Narr

Convertible Notes (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016		Dec. 31, 2015	Dec. 31, 2014		Dec. 31, 2013
Amortization of debt discount	$ 174,695	$ 117,348	$ 487,705	$ 375,140
Unamortized debt discount	$ 201,624		201,624		$ 143,419
Convertible Note
Additional paid in capital and discount			282,470
Amortization of debt discount			5,193	4,952
Amortization of debt discount, warrants			$ 3,545	$ 0
Warrants issued, value per share	$ 0.00583		$ 0.00583
Unamortized debt discount	$ 327		$ 327		8,937
Convertible notes payable	2,447,919		2,447,919		$ 2,375,000
Convertible Note | Non-Affiliate
Convertible notes issued	$ 153,000		$ 153,000
Convertible notes, interest rate	12.00%		12.00%
Maturity date			Jan. 5, 2019
Convertible notes payable	$ 183,600		$ 183,600
Convertible Note | Individually Issued
Convertible notes issued								$ 300,000
Convertible notes, payment terms								The note pays interest at a rate of 12% per annum, payable to the holder at 1% per month. The Company is making monthly payments of $5,000 towards the principal balance beginning June 1, 2014 until the note due date of February 27, 2018.
Convertible notes, price per share for conversion of shares of common stock								$ 0.15
Convertible notes, interest rate								12.00%
Maturity date								Feb. 28, 2018
Common stock issued								300,000
Convertible notes payable	125,000		125,000
Convertible Note | Series C Notes
Convertible notes issued								$ 95,000
Convertible notes, payment terms								Series C Notes bear interest at a rate of 12% per annum, payable to the holder at 1% per month, with principal amount due May 31, 2017.
Convertible notes, price per share for conversion of shares of common stock								$ 0.15
Convertible notes, interest rate								12.00%
Private placement, 12% convertible notes, principal amount							$ 20,000	$ 220,000	[1]
Maturity date								May 31, 2017
Common stock issued							240,000
Convertible Note | Series B Notes
Convertible notes, payment terms										Series B Notes pay interest at a rate of 12% per annum, payable to the holder at 1% per month.
Convertible notes, price per share for conversion of shares of common stock										$ 0.10
Convertible notes, interest rate										12.00%
Private placement, 12% convertible notes, principal amount										$ 2,230,000
Maturity date, description					The holders of $50,000 Series B Notes have agreed to extend the maturity date of the debt outstanding to September 1, 2017. The holder of $25,000 Series B Notes has agreed to extend the maturity date of the debt outstanding to September 1, 2019.		The holders of $1,840,000 Series B Notes have agreed to extend the maturity date of the debt outstanding to July 1, 2017 from its original maturity date of December 31, 2015.
Maturity date					Sep. 30, 2019		Jul. 1, 2017
Common stock issued										5,315,000
Warrants issued, shares					75,000	[2],[3]	1,840,000
Warrants issued, value per share					$ 0.07		$ 0.07
Exercise price							$ 0.0058
Unamortized debt discount					$ 285		$ 10,672
Convertible Note | Third Party Investor
Convertible notes issued	$ 60,237		$ 60,237
Convertible notes, price per share for conversion of shares of common stock	$ 0.025		$ 0.025
Conversion of debt, shares issued			4,140,000
[1]	$95,000, $75,000 and $50,000 of Series C Notes were sold on May 22, 2014, August 25, 2014 and October 31, 2014.
[2]	The 25,000 warrants issued are valued at $0.00583 per issued share.
[3]	The 50,000 warrants issued are valued at $0.00278 per issued share.

Royalty Financing (Details Narr

Royalty Financing (Details Narrative) - USD ($)	9 Months Ended		12 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2014	Dec. 31, 2016
Royalty Financing
Royalty purchase agreement, amount			$ 2,000,000
Royalty purchase agreement			On October 31, 2014, the Company entered into a royalty purchase agreement with Grenville Strategic Royalty Corp. for the amount of $2,000,000. The agreement calls for a monthly payment to the seller based on a percentage of the total of certain revenue items and subject to a minimum payment amount until $8,000,000 has been paid.
Royalty payments	$ 609,986
Discounted amortization expense	319,025	$ 232,175
Accrued royalties	467,014
Royalty purchase agreement, balance	2,326,448			$ 2,007,424
Royalty financing, unamortized discount	$ 4,983,828			$ 5,302,853

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - Major Shareholder - USD ($)	12 Months Ended
	Dec. 31, 2015	Sep. 30, 2017	Sep. 30, 2016
Consulting services, description	January 2015, the Company entered into an agreement with a company that is owned and controlled by a major shareholder, to provide consulting services. Fees payable for performance of the consulting services are $10,000 per month.
Stock options, granted	4,200,000
Stock options. granted, value	$ 34,683
Stock options, exercise price	$ 0.15
Stock options, contractual term	5 years
Stock price at grant date	$ 0.0517
Stock options, expected life	2 years 6 months
Stock options, volatility	70.00%
Stock options, risk free rate	0.03%
Balance for services rendered		$ 90,000	$ 90,000

Common Stock Transactions (Deta

Common Stock Transactions (Details Narrative) - USD ($)		9 Months Ended		12 Months Ended
		Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Conversion of convertible debt, shares issued, value		$ 112,240	$ 9,030
Bridge Convertible Promissory Notes
Shares issued, inducement	[1]			200,000
Shares issued, inducement, value	[2]			$ 9,030
Common Stock
Conversion of convertible debt, shares issued, value	[3]	$ 76,000
Conversion of convertible debt, shares issued, shares	[4]	5,740,000
Shares issued for services, shares		250,000		150,000	[5]
Shares issued for services, value		$ 23,750		$ 14,000	[6]
[1]	30,000, 70,000 and 100,000 shares issued on June 16, 2016, March 22, 2016 and February 18, 2016 as part of a bridge convertible note to a private investor.
[2]	Shares valued at $609, $1,421 and $7,000 as part of a bridge convertible note to a private investor.
[3]	$31,000 for value of shares issued May 23, 2017; $14,000 for value of shares issued July 6, 2017; $15,000 for value of shares issued August 16, 2017 and $16,000 for value of shares issued August 24, 2017.
[4]	1,240,000 shares issued May 23, 2017; 1,400,000 shares issued July 6, 2017; 1,500,000 shares issued August 16, 2017 and 1,600,000 shares issued August 24, 2017.
[5]	50,000 shares issued June 7, 2016 and 100,000 shares issued November 28, 2016.
[6]	$5,000 for value of shares issued June 7, 2016 and $9,000 for value of shares issued November 28, 2016 is $9,000.

Going Concern (Details Narrativ

Going Concern (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Total Comprehensive Income (Loss)	$ (714,301)	$ (259,182)	$ (1,573,590)	$ (610,048)
Working capital deficit	$ 6,237,521		$ 6,237,521